AstraZeneca's (AZN.L), opens new tab Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that has been the standard of care for 50 years, cutting the need for further treatment by 30%, according to a study published on Wednesday. The antibody drug known chemically as benralizumab was approved by U.S. and EU regulators in 2017 as a treatment for a severe form of the breathing disorder called eosinophilic asthma that targets a type of white blood cell associated with lung inflammation.
Read more
